MAGE-A4/MAGE-A8-targeted TCR-based bispecific T cell engager in recurrent and/or refractory solid tumors: a phase 1 trial

Journal:

Nature Medicine

Published:

2026-05-31

DOI:

10.1038/s41591-026-04455-x

Affiliations:

19

Authors:

27

Go to article

Institutions	Authors	Share
Immatics Biotechnologies GmbH, Germany	10.000000 10.000000	0.37
National Center for Tumor Diseases (NCT) Heidelberg, Germany	1.500000	0.06
TU Dresden, Germany	1.000000	0.04
Charité - University Medicine Berlin, Germany	1.000000	0.04
University Medical Center Freiburg, Germany	1.000000	0.04
University Hospital of Münster (UKM), WWU, Germany	1.000000	0.04
Comprehensive Cancer Center Mainfranken (CCC MF), JMU, Germany	1.000000	0.04
Marien Hospital Düsseldorf, Germany	1.000000	0.04
Klinikum Chemnitz gGmbH, Germany	1.000000	0.04
University Hospital Tübingen (UKT), Uni Tübingen, Germany	1.000000	0.04
University Hospital of Regensburg (UKR), Germany	1.000000	0.04
University Hospital Bonn (UKB), Uni Bonn, Germany	1.000000	0.04
Nuremberg Hospital, Germany	1.000000	0.04
Ulm University Medical Center, Germany	1.000000	0.04
Goethe University Frankfurt (GU), Germany	1.000000	0.04
University Hospital of Erlangen, FAU, Germany	1.000000	0.04
Heidelberg University Hospital at Medical Faculty Heidelberg, Uni Heidelberg, Germany	0.500000	0.02
TUM University Hospital Klinikum rechts der Isar (MRI), Germany	0.500000	0.02
Technical University of Munich (TUM), Germany	0.500000	0.02